Mereo BioPharma falls 10%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Mereo BioPharma Group (MREO.US) fell nearly 10% during regular trading to $0.2750.

The stock is up 13.87% over the past six months and down 34.01% year to date. It sits 88.40% below its 52-week high of US$2.370. Volume was 3.01 times its average.

The Nasdaq Composite is down 2.47% over the past five sessions and up 5.18% year to date.

An 8-K filing showed the company reported third-quarter fiscal 2026 revenue of $800,000.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.